YPEL4 Inhibitors
Chemical inhibitors of YPEL4 include a range of compounds that interfere with various signaling pathways and enzymatic activities within cells. Staurosporine operates as a broad-spectrum protein kinase inhibitor, which can lead to a decrease in YPEL4 activity by altering its phosphorylation state, assuming that YPEL4's function is modulated by phosphorylation. This action is complemented by Okadaic Acid and Calyculin A, both of which are known to inhibit protein phosphatases PP1 and PP2A. The inhibition of these phosphatases can result in increased phosphorylation levels of cellular proteins, which can lead to a decrease in YPEL4 activity if dephosphorylation is necessary for its functionality. Additionally, U0126 and PD98059 specifically target the MEK1/2 within the MAPK/ERK pathway. By inhibiting MEK, these compounds can decrease the phosphorylation of proteins that are downstream in the pathway, which can decrease YPEL4 activity if it is regulated by this signaling cascade.
Furthermore, LY294002 and Wortmannin both act as inhibitors of the PI3K/Akt pathway, which can lead to a decrease in YPEL4 activity if the protein is involved in this pathway. In the same vein, SP600125, an inhibitor of JNK, can decrease phosphorylation levels of proteins within the JNK signaling pathway, leading to a decrease in YPEL4 activity if it is regulated by JNK-dependent phosphorylation. SB203580's inhibition of p38 MAPK can also affect YPEL4 by disrupting signaling pathways that involve stress responses. Rapamycin, an inhibitor of the mTOR pathway, can lead to a decrease in protein synthesis and affect signaling pathways critical for cell growth, which can lead to a decrease in YPEL4 activity if it relies on mTOR signaling. Bisindolylmaleimide I, as a PKC inhibitor, can decrease YPEL4 activity by preventing PKC-mediated phosphorylation if YPEL4 is regulated by this kinase. Lastly, Genistein, a tyrosine kinase inhibitor, can decrease YPEL4 activity by inhibiting the phosphorylation on tyrosine residues, assuming YPEL4 activity is dependent on such modifications.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. YPEL4's functions could be regulated through phosphorylation; therefore, inhibition of kinase activity by Staurosporine may lead to a reduction in YPEL4 activity due to altered phosphorylation states. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid is an inhibitor of protein phosphatases PP1 and PP2A. By inhibiting these phosphatases, phosphorylation levels on proteins within the cell can be indirectly increased, which may result in functional inhibition of YPEL4 if it is regulated by dephosphorylation. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A sc-24000B sc-24000C | 10 µg 100 µg 500 µg 1 mg | $160.00 $750.00 $1400.00 $3000.00 | 59 | |
Similar to Okadaic Acid, Calyculin A inhibits protein phosphatases PP1 and PP2A, possibly increasing phosphorylation levels on proteins and potentially inhibiting YPEL4 activity if it relies on dephosphorylation for its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are kinases involved in the MAPK/ERK pathway. By inhibiting this pathway, U0126 could reduce phosphorylation of proteins that are downstream targets, indirectly affecting YPEL4's function if it is part of this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of the PI3K/Akt pathway. If YPEL4 is functionally integrated within this pathway, LY294002 could inhibit YPEL4 by reducing the pathway's activity, which might be crucial for YPEL4's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which may affect the MAPK/ERK pathway. Inhibition of MEK could lead to reduced activity of ERK and potentially inhibit YPEL4 if it is a downstream target in this pathway or dependent on ERK-mediated signaling for its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, one of the MAPKs. Inhibition of JNK activity could lead to reduced phosphorylation of proteins involved in JNK signaling, possibly causing functional inhibition of YPEL4 if it is regulated by JNK-dependent phosphorylation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 MAPK might affect YPEL4 function by interfering with signaling pathways that involve stress responses, potentially inhibiting YPEL4 if it is part of these pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor like LY294002. It could inhibit YPEL4 by disrupting the PI3K/Akt pathway, which may be necessary for YPEL4's function within the cell if YPEL4's activity is associated with this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. Inhibition of mTOR can lead to decreased protein synthesis and affect signaling pathways important for cell growth and proliferation. This could indirectly inhibit YPEL4 if it requires mTOR signaling for its function. | ||||||